Latest Life Sciences News

Page 2 of 21
Keysight Technologies has tapped long-time finance executive Jason Kary to replace CFO Neil Dougherty, who is stepping down for personal reasons. The company has left its fiscal fourth-quarter outlook unchanged ahead of results on November 19.
Sophie Babbage
Sophie Babbage
3 Nov 2026
Healthpeak has raised its 2026 adjusted FFO and same-store NOI guidance after a quarter of strong senior housing growth, leasing activity and portfolio expansion. The uplift comes with a lower GAAP earnings outlook, reflecting depreciation from newly acquired senior housing assets.
Eva Park
Eva Park
3 Nov 2026
EZZ Life Science cut its quarterly operating cash outflow sharply despite a 37.7% drop in customer receipts, as weaker Chinese e-commerce sales continued to weigh. EAORON skincare growth and a $9.16 million cash balance offer some support, but distributor collections and potential product returns remain unresolved.
Victor Sage
Victor Sage
30 Oct 2026
Xenitra has returned to positive quarterly gross profit as its new pharmaceutical and Web3 businesses begin generating revenue, but statutory operating cash flow remained negative at A$790,000. The company is now relying on procurement targets, repeat Web3 sales and further capital discipline to turn early commercial activity into sustainable cash generation.
Victor Sage
Victor Sage
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
AnteoTech reported a quarter of technical milestones and commercial discussions across its battery and life sciences businesses, including new agreements with Xerabrid and Airspeeder. The company ended September with about A$11 million in cash, although an inconsistency in the Appendix 4C reconciliation needs clarification.
Victor Sage
Victor Sage
29 Oct 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
Genetic Signatures has added a new AGM resolution seeking approval to issue up to 340.7 million shares and 129.7 million options under its proposed Microba merger. The all-scrip transaction remains non-binding and subject to further shareholder, court, regulatory and due diligence conditions.
Ada Torres
Ada Torres
23 Oct 2026
Anatara Lifesciences narrowed its FY2026 loss and ended the year with A$470,917 in cash, but warned that further capital raising is included in its business plan and may be necessary to remain a going concern. Its AOC anti-obesity candidate produced statistically significant results in mice, while mechanism-of-action data remained inconclusive and development was placed on hold.
Victor Sage
Victor Sage
23 Oct 2026
Genetic Signatures and Microba Life Sciences have agreed in principle to revise their proposed merger, reducing Microba shareholders’ post-deal ownership from about 67% to 60%. The change improves the position of existing GSS shareholders, but the transaction remains non-binding and subject to multiple approvals.
Victor Sage
Victor Sage
21 Oct 2026
Microba has secured a $2.025 million placement while cutting costs further, launching GI Navigator and advancing its proposed merger with Genetic Signatures. The funding comes as the company reports strong Australian testing growth but only about one quarter of cash cover before the raise.
Victor Sage
Victor Sage
20 Oct 2026
Genetic Signatures says its existing directors will resign if BCAL nominees become a majority after the 28 October EGM. The company is also demanding clarity on whether BCAL intends to merge with GSS, pointing to the stark difference between the two companies’ cash runways.
Ada Torres
Ada Torres
16 Oct 2026

Browse the archive

Full archive